Crown Wealth Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-5,184
Closed -$266K 77
2022
Q4
$266K Sell
5,184
-12
-0.2% -$575 0.25% 48
2022
Q3
$227K Buy
5,196
+29
+0.6% +$1.41K 0.23% 53
2022
Q2
$271K Buy
5,167
+366
+8% +$18.7K 0.25% 53
2022
Q1
$249K Buy
+4,801
New +$249K 0.17% 80

Other funds holding PFE

Crown Wealth Group's PFE Position: Q1 2023 in Review

Crown Wealth Group sold out of Pfizer (PFE) in Q1 2023, closing a stake of 5,184 shares — an estimated $266K sold.

Crown Wealth Group first reported a position in PFE in Q1 2022 and held it in 4 quarters. The position peaked at $271K in Q2 2022. 3,102 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

  • Crown Wealth Group reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
  • Crown Wealth Group sold 5,184 Pfizer shares in Q1 2023, an estimated $266K.
  • Crown Wealth Group first reported a position in Pfizer in Q1 2022 and held it in 4 quarters.
  • Crown Wealth Group's Pfizer position peaked at $271K in Q2 2022.
  • 3,102 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on Crown Wealth Group's 13F filing for Q1 2023, filed 28 Apr 2023.